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ABSTRACT
Due to a genetic mutation, a rare and potentially fatal disease has spread
throughout New Mexico. This disease, Familial Cerebral Cavernous Malformation
(FCCM1-CHM), is due to a mutation that affects peoples of Hispanic heritage in New
Mexico. The FCCM disease is characterized by the development of dilated, thin walled,
leaky vessels that occur in the brain and spinal cord. As a result of this genetic
mutation, the lesions in the blood vessels of the brain and spinal cord are highly
susceptible to hemorrhaging into surrounding tissue. This can lead to headaches,
seizure, and possibly death. Researchers at the University of New Mexico have
identified skin lesions in the FCCM positive population (Zlotoff et al., 2007). The
relationship between these skins lesions and the FCCM genetic mutation has not been
thoroughly established. If these skin lesions can be characterized they may serve as a
non-invasive screening tool that can be developed to diagnose and monitor this
insidious disease. The long-term goal of this research project will be to develop a tool to
aid community physicians in the early diagnosis and management of this life threatening
disease. The overall objective of the study is to describe the relationship between
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cutaneous vascular lesions and central nervous system lesions. The central hypothesis
proposed by the study is that the number of skin lesions of varying CCM characteristic
morphology is positively correlated with the number of brain lesions. We plan to test this
hypothesis by utilizing a cross sectional study of FCCM positive patients in New Mexico.
The rationale for this study is that if we can prove an association of a skin marker
with this deadly disease, then this association may present an opportunity for an easier
and earlier diagnosis of the disease. The central hypothesis of the study is tested with
two specific aims that are descriptive and exploratory in nature. 1) To develop a
database of photographs of skin lesions in FCCM positive subjects. Previous research
on a related population of FCCM skin lesions has determined that lesions of three
different types exist: hyperkeratotic cutaneous capillary-venous malformations
(HCCVM), capillary stains, or deep blue nodules (Sirvente et al., 2009). This research
will identify the different qualities of the cutaneous lesions to attempt to identify the
types of lesions associated with the FCCM1-CHM disease. 2) To determine a
relationship between skin lesions and brain lesions. It is critical that we determine a
relationship between the skin lesions and the potentially fatal brain lesions. The working
hypothesis is that the quantity of skin lesions positively correlates with the number of
brain lesions. If an association can be established between this disease and skin
lesions, a simple skin exam may serve as a complementary, innovative approach to
diagnosing and monitoring this disease. The significance of this study is that we aim to
identify a novel clinical finding, i.e. skin lesions, that may be associated with the
potentially fatal FCCM disease in the New Mexican population.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
The CCM1-CHM genetic variant of this disease is considered endemic to the
New Mexico area. The CHM abbreviation stands for the “Common Hispanic Mutation”.
This autosomal dominant genetic disease has been relatively recently discovered and
associated with the native New Mexican population. Although the exact origins of the
disease are not known, genealogic research studies conducted in New Mexico CCM
families suggest that the gene coding for the vascular mutation originated in a common
ancestor from Spain who relocated to Mexico in the 1500s, traveled up the El Camino
Real, and settled in New Mexico. Because of this genetic founder type mutation, as well
as its autosomal dominant transmission of disease, CCM1-CHM has become a large
public health burden in the State of New Mexico (Akers et al. 2013). Although the
disease has spread through the Hispanic population in New Mexico, some of the
original families known to have the disease were the “Baca”, “Romero” and “Sanchez”
families. In its truest essence, FCCM is a community-based disease.
Cavernous malformations (CM) are diseases characterized by the development
of dilated, thin walled, leaky vessels lined by a single layer of endothelium and without
intervening neural tissue (Grippaudo et al., 2013; Toll et al., 2009). These malformations
occur in the venous-capillary bed, consisting of enlarged channels or caverns with no
parenchymal support and slow blood flow, prone to thrombosis and other pathologies
(Clatterbuck, Eberhart, Crain, & Rigamonti, 2001; Fischer, Zalvide, Faurobert, AlbigesRizo, & Tournier-Lasserve, 2013).

1

A

B

C
Figure 1. (A) Histology of a facial lesion from a patient with CCM showing a single large
dilated vascular channel with a flat endothelial lining in the upper dermis. Haematoxylin-eosin
stain x40. (B) Histology of a vascular lesion on the arm from a patient with CCM.
Haematoxylin-eosin stain x40. (C) Histology of a post-mortem brain sample showing a
juxtaposition of dilated vascular structures lined by a single layer of endothelial cells and
collagen. Haematoxylin-eosin stain x100. (Toll et al., 2009)

Figure 1 demonstrates the cutaneous histological manifestation of this disease.
The CCM disease pathogenesis is directly linked due to the leaky vessels in the brain
and spinal cord. The turbulence in flow caused by the malformed blood vessels can
lead to blood stasis or even ballooning of these vessels. These occurrences can be
potentially life threatening. The histology of these lesions both in the dermis and the
brain are similar. Biopsy of CCM skin lesions at the University of New Mexico has
2

shown these skin lesions to be similar in morphology as other skin lesions in other
FCCM positive populations.
The brain is the most common site of these lesions in the nervous system, which
also occur in arachnoid matter, the pia matter, and the spinal cord, and are referred to
as Cerebral Cavernous Malformations (CCM) (Grippaudo et al., 2013; Toll et al., 2009).

Figure 2. Cerebral Cavernous Malformation graphic demonstration in the brain. (Dartmouth-Hitchcock,
2014)

These vascular lesions clinically manifest as hemorrhages, seizures, headaches,
or focal neurological deficits. However, lesions are often asymptomatic, which is why
diagnosis is difficult without clinical suspicion or without other physical manifestations.
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The following images demonstrate the appearance of these lesions in the cerebral
cortex. MRI examination is the gold standard for visualizing the size and number of
lesions in the brain and spinal cord. Additionally, these lesions can occur in non-neural
tissues, such as in the retina, vertebrae, and cutaneous tissue.

Figure 3. Left image: T2-weighted coronal magnetic resonance imaging study showing areas of heterogeneous
signal intensity with T2 hypointense rims consistent with cerebral cavernous malformations (Whitworth et al.,
2015).
Right image: MRI examination from patient 1 showing cerebral hypo-intense images corresponding to cavernomas.
(Clatterbuck, Cohen, Gailloud, Murphy, & Rigamonti, 2002; Whitworth, Hick, Nelson, & Sidhu-Malik, 2015).

CCMs are thought to occur between 0.1% and 0.8% of the world population
(Ebrahimi et al., 2009; Rigamonti et al., 1987), with symptoms typically developing
between the second and fifth decades of life (Rigamonti, Johnson, Spetzler, Hadley, &
Drayer, 1991; Zabramski et al., 1994). There are two forms of the disease: sporadic and
familial (Labauge, Denier, Bergametti, & Tournier-Lasserve, 2007). The sporadic form
accounts for 80% of CCMS cases, and the familial form, called Familial Cerebral
Cavernous Malformations (FCCM), accounts for the remaining 20% (Fischer et al.,
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2013). On cerebral magnetic imaging (MRI), the familial form typically presents with
multiple lesions, whereas the sporadic form usually present with a single lesion,
although some sporadic cases have been reported with the presence of multiple lesions
(Labauge et al., 2007).
FCCM cases have been reported across the globe. In China, 25 members of a
family with CCMs underwent imaging and genomic studies, which revealed intracranial
lesions in seven members, all of which had multiple lesions, and four of which had
accompanying skin hemangiomas. The clinical manifestation was across a wide range,
and the lesions were at various stages of illness evolution. Moreover, a novel T deletion
mutation was seen in exon 14 of the CCM1 gene in the seven patients with brain
lesions detected by MRI, and these mutations were not seen in the healthy controls
(Wang et al., 2013). In Italy, three family members were found to have CCM after
undergoing evaluation for seizures. They were found to have a mutation in the PDCD10
gene consisting of a deletion of four base pairs in exon 7 (c.334_337del) which results
in a premature stop codon due to a frame-shift, and that mutation was absent in the
healthy family members (Garaci et al., 2015). Likewise in Saudi Arabia, a frame-shift
mutation at C.1249_125delAAAC, also leading to premature protein termination
(p.Lyse417HisfsStop19) (Nahrir, Al-Hameed, Al-Sinaidi, & Al Shakweer, 2013). The
finding of this KRIT1/CCM1 mutation in the two Saudi families illustrated that CCM
exists beyond the common CCM geographical areas.
In another study conducted in Germany, examination of a series of 105 index
cases of CCM revealed several other mutations in CCM1 (60%), CCM2 (18%), and
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CCM3 (22%) (Spiegler et al., 2014). The same study revealed that 32% of the cases
were a stop mutation, 34% were a frame-shift mutation, 28% were a splice site mutation
resulting in a frame-shift, and 4% resulted in a large genomic deletion. However, one of
the highest population densities of people with cerebral cavernous malformations is in
New Mexico, USA. Preliminary investigation has shown that CCM1-CHM has an
estimated population prevalence of 15/100,000 (Akers et al. 2013).
In a cohort of French patients, approximately 9% of patients with CCM were
found to have associated cutaneous vascular malformations. This sample included
individuals with various gene mutations in CCM1, CCM2, and CCM3. Researchers
described 3 specific phenotypes. The phenotypic morphologies reported included:
hyperkeratotic cutaneous capillary-venous malformations (HCCVM), capillary stains,
and deep blue nodules (Sirvente et al., 2009). In 2007, a group led by Dr. Barrett Zlotoff
reported a case of a cutaneous vascular malformation in a patient with CCM1-CHM
(Toll et al., 2009). Dr. Zlotoff’s group has observed all three phenotypic morphologies of
vascular malformations in CCM1-CHM patients that were noted in the French cohort.
Dr. Leslie Morrison at the University of New Mexico is currently conducting a natural
history study of patients diagnosed with CCM1-CHM. Preliminary data indicates that
32% of individuals studied (n=140) have one or more cutaneous vascular
malformations. This estimate is much higher than the 9% reported by Sirvente and
colleagues. The images below are cutaneous findings from a French population of CCM
positive persons. In this populations port wine stain like cutaneous lesions are present
in addition to HCCVM, capillary stains, and deep blue nodules.
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While the sporadic form does not carry a germline mutation in CCM genes, three
main genes have so far been identified for the FCCM form: CCM1 on chromosome
7q21, CCM2 on 7p13-15, and CCM3 on 3q25-27 (Bergametti et al., 2005; Grippaudo et
al., 2013; Sirvente, Enjolras, Wassef, Tournier-Lasserve, & Labauge, 2009). The familial
form is inherited in an autosomal dominant pattern with incomplete penetrance and
variable expressivity and is more common in Hispanic-Americans (50%) than in
Caucasians (10-40%) (Grippaudo et al., 2013; Rigamonti et al., 1988). These three
CCM genes code for three respective proteins that form a trimeric protein complex. It
was shown that in endothelial cells, these CCM proteins regulate the cytoskeleton, as
well as control polarity, migration, and junction stability (Glading, Han, Stockton, &
Ginsberg, 2007; Hilder et al., 2007; Richardson, Dibble, Borikova, & Johnson, 2013).
For correct functioning, all three proteins should be cohesively and properly expressed
(Baranoski, Kalani, Przybylowski, & Zabramski, 2016).
The pathophysiology of CCM is complex and involves multiple biochemical
pathways that lead to disease manifestation. A common defect with the loss of either
CCM1, CCM2, or CCM3, is a resultant increase in RhoA activity (Richardson et al.,
2013). RhoA is a GTPase that activates Rho-associated coiled coil-forming kinase
(ROCK), which results in increased stress fiber formation, which functionally results in
endothelial cells with inability to form three-dimensional tubes and form stable
permeability barriers (Stockton, Shenkar, Awad, & Ginsberg, 2010).
Additionally, in CCM1, the mutation occurs at the KRIT1 gene, which codes for a
protein thought to be involved in stabilization of cellular junctions and physiological
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angiogenesis (Lan et al., 2010). Studies involving Hispanic and Mexican-American CCM
patients have revealed a “common Hispanic mutation” in CCM1 (CCM1-CHM).
Mutational analysis revealed this mutation as a C-to-T transition in exon 6 at nucleotide
742 of the KRIT1 gene (Q248X), predicted to result in a premature termination codon
for glutamine (Sahoo et al., 1999). This mutation has autosomal dominance with a
clinical penetrance of approximately 60% (Riant, Bergametti, Ayrignac, Boulday, &
Tournier-Lasserve, 2010).
This mutation results in loss of function of the KRIT1- protein, which is expressed
in arterial and venous endothelial cells and present in intercellular junctional proteins.
KRIT1 interacts with integrin cytoplasmic protein-1 (ICAP1). Integrins are a group of
transmembrane proteins that attach the cell’s cytoskeleton to the extracellular matrix
(ECM), as well as other physiologic role, such as cell signaling, embryogenesis, and
tissue formation and repair (Baranoski et al., 2016; Liu, Draheim, Zhang, Calderwood, &
Boggon, 2013). ICAP1 usually binds to integrin and suppresses its activation.
KRIT1 affects ICAP1 in two ways: (1) when KRIT1 is active, it binds ICAP1,
preventing it from over-suppressing integrin, therefore resulting in normal integrin
activation and cell to ECM connection (Baranoski et al., 2016); and (2) KRIT1 also
stabilizes ICAP1, preventing its under-activation and ensuing under-suppression of
integrin. The resultant over-activation of integrin (specifically β1 Integrin) also leads to
defective cell to ECM interaction (Faurobert et al., 2013). Unregulated β1 Integrin also
leads to an increased and aberrant angiogenesis (Renz et al., 2015) . Thus, loss of
KRIT-1 leads to unstable junctional integrity, and increased endothelial permeability
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(Glading et al., 2007). This mutation has autosomal dominance with a clinical
penetrance of approximately 60% (Riant et al., 2010).

Figure 4. Functions of CCM proteins in endothelial cells. CCM1 and CCM2 are essential to control barrier
junctions by several means. The proteins inhibit RhoA-Rho kinase activity, and stabilize adherens junctions and
tight junctions. CCM1 is necessary for proper DLL4-Notch signaling. CCM3 can interact with CCM2 but also form
a complex with PP2A phosphates and GCKIII kinases Mst4, STK24, and STK25, which phosphorylate Moesin to
inhibit Rho kinase activity. All three CCM proteins execute important functions to control angiogenesis and to
maintain the endothelium in a functional, quiescent state (inhibition of proliferation, migration, and angiogenesis;
prevention of vascular barrier functions and integrity). Additionally, CCM1 and in particular its interactions partner
ICAP1 is involved in cell adhesion and extracellular matrix remodeling (Fischer et al., 2013).

Furthermore, KRIT1 also contributes to the pathology of CCM by interacting with
HEG (heart of glass receptor) which is essential for localization of KRIT1 to endothelial
cell-cell junctions (Gingras, Liu, & Ginsberg, 2012); by regulating Notch signaling
pathway, which is reduced in KRIT1 deficiency, resulting in irregular vascular sprouting
and abnormal angiogenesis (Baranoski et al., 2016); and by regulating pathways
involved in the control of reactive oxygen species production, where KRIT1 deficiency
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leads to a decrease in superoxide dismutase-2, which scavenges harmful reactive
oxygen species that would otherwise contribute to the severity of tissue injury
(Baranoski et al., 2016; Goitre et al., 2010).
The CCM2 gene codes for the CCM2/malcavernin protein, which are needed by
endothelial cells for cytoskeletal structure, cell-cell interaction, and blood vessel
formation (Baranoski et al., 2016; Liquori et al., 2003). Specifically, CCM2 inhibits
MEKK3, a pathway which leads to increased and irregular endothelial cell expression
when over-expressed (Baranoski et al., 2016; Zhou et al., 2015). CCM2 also binds to
Programmed Cell Death Protein 10 (PDCD10), which is the product of CCM3, ensuring
proper signaling and endothelial cell function (Baranoski et al., 2016; Draheim et al.,
2015).
PDCD10 is needed for normal migration of radial glia and pyramidal neuronal
cells, and loss of PDCD10 results in abnormal cellular morphology due to dysregulation
of the actin and microtubule cytoskeleton (Baranoski et al., 2016; Louvi, Nishimura, &
Gunel, 2014). PDCD10 is also involved in neural migration by suppressing RhoA
signaling (Louvi et al., 2014).
Emerging evidence has also shown that three miRNAs are essential for the
pathological development of CCM (Kar et al., 2017). These miRNAs, identified as let7b-5p,

miR-361-5p,

and

miR-370-3p,

have

been

shown

to

be

significantly

downregulated in CCM, and it is thought that this contributes to the pathology via the
miRNA-mRNA interaction with resultant unbalanced translation (Kar et al., 2017).
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Of the three mutations that lead to CCM, patients with CCM due to a CCM3
mutation have the most aggressive illness compared to those with the CCM1 or CCM2
forms, as well as earlier onset of symptoms and a higher number of lesions (Shenkar et
al., 2015). However, up to 50% of subjects with FCCM remain asymptomatic throughout
their lifetime (Morrison & Akers, 1993).

Port-Wine Stain: well demarcated
Red macule of the neck.

Punctuate capillary formation: punctate
reddish-colored macule of the forearm.

Punctuate capillary malformation:
punctuate dark brown-colored macule of
the thigh.

Multiple plaque-like irregularly shaped Bluish discoloration of the peripheral
Black-colored lesions of the left forearm. skin around the same lesions of the left arm

Figure 5. Examples of skin lesion exhibited in other CCM positive cohorts. (Sirvente et al., 2009)

While the frequency and phenotypes of vascular malformations have been
studied in other cohorts, they have not been extensively studied in a cohort of patients
11

that carry one specific gene mutation. One of the aims of this study will be to
characterize the prevalence and classify the types of these lesions within a population
of CCM1-CHM patients.

Due to the geographic founder effect, these lesions are

fundamentally homogenous in terms of the causal genetic mutation. This rare situation
offers a unique opportunity to obtain much more unique data then obtained in previous
studies. Access to this large, homogenous population will allow the research group to
determine the quantity and characteristics of cutaneous malformations that occur in this
population. Photographing cutaneous vascular malformations is thus a necessity to
establishing a catalog, which could be valuable for early detection of individuals who
inherited CCM1-CHM. Identification of cutaneous vascular malformations could serve
as a less invasive way to screen for CCM.

This database can also be used to

understand any associations between cutaneous vascular malformations and symptoms
associated with CCM (e.g., seizure, stroke).
SIGNIFICANCE TO PREVENTIVE MEDICINE IN NEW MEXICO
The importance of carrying out this study is paramount to the ensuring the
preventive health of thousands of people in the Hispanic population of New Mexico.
Currently, the method of determining whether or not a person carries the CCM mutation
is determined with a saliva sample that is sent for genetic testing. This analysis is
expensive and thus impractical to implement as a screening tool. If my research group
is able to identify a correlation between certain types of skin lesions and the CCM
disease, we would be able to use this knowledge as a screening tool.
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Educating dermatologists and primary care physicians would be the next step in
ensuring that this information was implemented as a preventive health tool in the
medical community. The screening would take place in the form a simple skin
examination and current medical and family history that could then lead the health
practitioner to request saliva sample for testing. The implementation of this skin exam
can be considered analogous to utility of a colonoscopy in screening for colon cancer. If
implemented in the clinical setting this research will undoubtedly lead to earlier
detection of an insidious and possibly fatal disease in the New Mexican population.
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CHAPTER 2
METHODOLOGY
LITERATURE SEARCH STRATEGY
Pubmed is a reliable and thorough database for researching topics in medicine.
Therefore, this database was used as a gateway to more knowledge about this rare
disease. Specifically I used the Mesh database and used the simple search line “familial
cerebral cavernous malformations” as an opening search. I selected the "Restrict to
Mesh Major Topic" and added it to the search. Because this research aims to identify
the association of skin lesions cerebral cavernous malformations, my primary goal was
to ascertain any previously discovered associations. Thus I added “cutaneous” to the
search builder to mesh the two terms. Reasonable limitations were then incorporated.
The limits used were “humans and English”. The PubMed database provided me with
relatively many articles related to this rare disease. What I discovered in my research
and what I would consider an oversight on my part is that I am attempting to study the
genetic form of this condition. There exists a spontaneous mutation that results in these
cerebral vascular malformations. When I searched using the term “ cerebral cavernous
malformation” I found 1583 articles. By incorporating the term “familial” (denoting a
genetic origin) I retrieved much less and more relevant articles. When I incorporated the
aforementioned term I received 286 articles. Again the topic of investigation is the
association of cutaneous lesions and brain lesions. I believed that this would very much
so limit the amount of papers on the subject. I was right in this respect as a mesh
database search revealed 23 articles. Out of these 23 articles I was able to reduce the
14

amount of articles to 15 for inclusion in my research. I am researching a very specific
topic that to date, has not had much published research. Additionally I attempted to
investigate a relatively unknown association of the disease, that is the skin
manifestation. For this reason I wanted to do an initially broad search that would capture
all the research in the subject. A little less than half of the papers I reviewed for final
inclusion in my research concentrated on the genetic origin of the brain and skin
lesions. My research topic focuses more so on the phenotypic expression of the
disease: the cutaneous lesions. The point of my proposed research is to identify the
relationship between the cutaneous lesions and the brain lesions. Interestingly enough
the few case reports found proved to be most helpful, as many of them detailed the
number and type of cutaneous lesions. Only three of these case reports gave a number
of cutaneous lesions and brain lesions. In all of my research I did not find one paper that
has a pooled population that compared that number of lesions. This is expected being
that this research is novel in origin. It seems that the question has not yet been formally
hypothesized and studied. This offers a unique situation to produce innovative research
on the topic.
SIGNIFICANCE
One of the highest CCM population densities is in New Mexico where it
disproportionately affects those of Hispanic descent. Although the prevalence of the
disease is not known in New Mexico, genealogic research has estimated that tens of
thousands of people may carry the genetic mutation. Due to the existence of relatively
isolated communities, this autosomal dominant disease has been passed on throughout
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generations of families. In a cohort of French patients, approximately 9% of patients
with CCM were found to have associated cutaneous vascular malformations (Sirvente
et. al, 2009). While the frequency and phenotypes of cutaneous vascular malformations
have been studied in other cohorts, they have not been extensively studied in a cohort
of patients that carry one specific gene mutation, such as the CCM1 - CHM mutation in
New Mexico. The research group believes it would be valuable to characterize the
prevalence and classify the types of these lesions within the New Mexican population of
FCCM1-CHM patients. Due to the geographic founder effect, the loss of genetic
variation that occurs when a very small number of individuals from a larger population
create a sub population, these lesions maybe fundamentally homogenous in terms of
the causal genetic mutation. This rare situation offers us an opportunity to obtain much
more unique data than obtained in studies which included individuals with varied FCCM
mutations. Access to this large, homogenous population allowed us to determine the
quantity and characteristics of cutaneous malformations that occur in this population.
The significance of this study is that we aim to identify a novel clinical finding,
characteristic skin lesions, that may be associated with the potentially fatal FCCM
disease in a specific New Mexican population. If an association is found this may help
us to develop a simple clinical screening method to help us diagnose and monitor this
disease. The results of the study have the propensity to be useful to the management of
other CCM positive cohorts throughout the world.
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INNOVATION
The study population in New Mexico, which is comprised of individuals carrying
homogenous CCM1-CHM mutation, offers a uniquely innovative opportunity to study the
FCCM disease. One of the mainstream current methods to diagnose the FCCM disease
is a saliva based genetic test. This test often times takes several weeks to months to
produce results. Once the diagnosis is confirmed by genetic testing, serial fMRI’s are
performed to monitor the evolution of the disease (Hart et. al, 2013). If an association
can be established between this disease and skin lesions, a simple skin exam may
serve as a complementary yet innovative approach to screening for this disease. Our
research group does not intend to substitute genetic testing for definitive diagnosis;
rather it aims to provide a less invasive clinical screening tool for providers. A general
community physician and dermatologist alike are competent in completing a skin exam.
Thus the potential utility of the skin exam to help elucidate a CCM diagnosis is universal
in the medical field. Photographing and describing these lesions and understanding the
association between cutaneous vascular malformations and cerebral malformations is
thus a necessity to establishing a lesion catalog, which could be valuable to educate
physicians and allow for early detection of individuals who inherited this potentially lethal
disease. A review of the literature reveals that correlating the number of cutaneous
lesions with cerebral lesions has not been done in similar genetic diseases. If an
association can be proven between the lesions, this could serve as a novel approach to
understanding other neuro-cutaneous diseases.
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APPROACH
Aim #1: To develop a catalogue of photographs of skin lesions in CCM1-CHM
positive subjects.
Introduction. Phenotypes of cutaneous vascular malformations have been
studied in other FCCM positive cohorts (Grippaudo et. al, 2013). However they have
not been extensively studied in a cohort of patients that carry the Common Hispanic
Mutation. The research group believes it would be valuable to characterize the
prevalence and classify the types of these lesions within this population of FCCM
patients in New Mexico. Previous research on a related population of FCCM skin
lesions has determined that lesions of three different types exist: hyperkeratotic
cutaneous capillary-venous malformations (HCCVM), capillary stains, or deep blue
nodules (Sirvente et. al, 2009). In this cohort of French patients, approximately 9% of
patients with CCM were found to have associated cutaneous vascular malformations.
This sample included individuals with various gene mutations in CCM1, CCM2, and
CCM3. The patient sample consists solely of the CCM1 – CHM genotype. The
preliminary data indicates that the prevalence of these typical skin lesions is much
higher. Preliminary clinical data indicates that 32% of individuals studied (n=140) have
one or more cutaneous vascular malformations. This estimate is much higher than the
9% reported by Sirvente et al. Photographing cutaneous vascular malformations will
establish a database of research information that can be used to characterize the type,
prevalence, and common location of these characteristic lesions. The objective of this
aim is to identify the prevalence and morphology of the aforementioned skin lesions in
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the FCCM population. We will test the working hypothesis that skin lesions of multiple
different variants are positively correlated with the Familial Cerebral Cavernous
Malformation CCM1- CHM disease. The rationale for this study is that if we can prove
an association of characteristic skin markers with this deadly disease, then this
association may present an opportunity for an easier diagnosis of the disease. It is an
expectation that this research will promote earlier detection of this disease.
Research Design. We conducted a cross-sectional study of patients enrolled in a CCM
type 1 common Hispanic mutation
(CCM1-CHM) database/Registry of
500 individuals, which has been
assembled as part of the NIH-funded
Rare Diseases Clinical Research
Network Protocol #6201. This study
incorporates research data on persons
that have already been enrolled in the
study while continuing to enroll new
patients in the study. In that respect
the study is classified as a cross

Figure 6.

sectional cohort study. The University of New Mexico IRB had approved the research
group’s consent and assent forms. A member of the research team that the IRB had
approved conducted the consent/assent process. The process most often occurred in
the clinic prior to the skin examination. The study is based on a convenience sample of
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patients that have clinical appointments that occurred approximately once a month at
the University of New Mexico’s Clinical Neuroscience Center. Patients were also
examined for cutaneous lesions at the CCM Family Conference held in June 2013 and
April 2017. The participants seen in June 2013 provided the research group with a
preliminary example of cutaneous lesions in this specific population. This data was
eventually incorporated in the final analysis. Patients were not selected for clinic
appointments based on age, gender or any other qualifier. Inclusion criteria will thus be
anyone of the CCM1-CHM positive individuals from the aforementioned patient pool.
Persons of all ages were included in the study. Both males and females were included
in the study.
Specifically, the inclusion criteria were:
a) Individuals diagnosed with CCM1-CHM that is confirmed by DNA testing.
Recruitment was targeted to individuals with confirmed CCM1-CHM based upon
saliva DNA testing. Both individuals who have and do not have cutaneous
vascular malformations were included in the study. Those who had a vascular
cutaneous malformation, which was determined by asking individuals with
CCM1-CHM if they have any blue, purple or red marks, underwent a broad visual
observation of exposed skin areas prior to consent into the study. Only those with
presumed vascular cutaneous malformations were consented and subsequently
photographed.
Exclusion criteria included:
a) Individuals who are incarcerated.
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b) Individuals who are pregnant.
c) Individuals who do not want have any vascular cutaneous malformations.
d) Individuals who do not want to have their vascular cutaneous malformations
photographed.
Photographs were taken with a high-resolution digital camera. The photographs
were reviewed to ensure clarity and ease of interpretation. Special attention was paid to
ensure that no identifying features of the patient were included in the photograph.
Occasionally, multiple photographs were taken of one cutaneous vascular malformation.
If a skin finding was questionable for a CVM it was photographed and included on initial
data collection. All lesions included at least one picture with a ruler to determine the size
of that particular lesion.
Once photographs were taken of the patient’s cutaneous vascular malformations
they were uploaded using secure password protected computers to the secure
computer drive within 24 hours. The photographs were assigned a random number and
the digital image was erased from the camera’s memory card. The digital photographs
were then stored on password-protected drives in the UNM Neurology Department. In
an effort to minimize the risk of loss of patient privacy the photographs of the lesions
were kept separate from the patient’s electronic chart. A study number was assigned to
a photograph that allowed only qualified study researchers to associate the photograph
with a particular patients’ electronic chart. Any identifying factors were blurred or black
boxed to maintain anonymity. An example of this could be any photographs that could
include facial features. Lesions in these areas were recorded in the patient file but no
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photographs with identifying features will be published in research journals or any other
public outlet.
Identifiable data was available only to research personnel approved for the study.
The patient’s skin examination consisted of the head, face, trunk, lower and upper
extremities. We did not examine the genitalia of males or females as well as women’s
breasts. Photographs of the skin lesions were taken, and size, quantity, and morphology
were recorded. The size of the lesions was measured in vivo with a standardized ruler.
The research group used the same ruler in each photograph so as to standardize for
lesion size. To ensure validity, Dr. Barrett Zlottoff, a dermatologist who specializes in
FCCM cutaneous vascular lesions, reviewed the digital images of the lesions. The type
of technology our research group incorporated to have the images reviewed by a
dermatologist is known as store and forward teledermatology. Store and forward is a
secure way of sending data that is based on a hospital’s existing email system. The use
of teledermatology has become commonplace in the clinical medicine world. Store and
forward teledermatology is simply the act of taking a digital image via a camera and
using electronic means to send the image to another provider for review. The published
literature on this technique has shown it to be comparable to in person examination and
diagnosis. A publication by Whited in 2015 demonstrated that teledermatology has been
found to be a diagnostically reliable means of diagnosing skin conditions (Whited,
2015). The research group is confident that this technique provided accurate results.
Outcomes. It is anticipated that the research group will have documented and
described the types of aforementioned characteristic CCM skin lesions that occur in the
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New Mexican FCCM1-CHM patient population. The identification of characteristic CCM
skin lesions may serve as a less invasive and preemptive way to diagnose FCCM.
Aim #2: To determine a relationship between skin lesions and brain lesions.
Introduction. It is critical that once we established a library of FCCM skin lesions that
we attempted to identify whether there is a relationship between the skin lesions and the
potentially fatal brain lesions. We will test the working hypothesis that the number of
characteristic skin lesions identified, positively correlates with the number of brain
lesions. The rationale for this aim is that if we can prove an association of a skin marker
with this deadly disease, then this association may present an opportunity to make
inferences on how many brain lesions an individual has. A thorough review of the
literature reveals that no other research group has attempted to investigate the
relationship of skin lesions and brain lesion in a CCM population. It is an expectation
that this research will continue to provide us with a novel approach to evaluating the
extent of the potentially deadly FCCM disease.
Research Design. Once the catalogue of skin lesions in the FCCM population was
established as defined in AIM #1, we compared this information with the MRI results of
patients enrolled in the CCM1-CHM database. The MRI is specifically a dynamic
contrast-enhanced MRI that is able to visualize cerebral cavernous malformation
lesions. Unlike the skin CCM lesions, these lesions are uniform in the type of lesion.
The two characteristics of the cerebral CCM lesions that are identifiable by MRI are the
size of the lesion and whether the lesion is actively bleeding or not. As previously
discussed, no associations have been made between the brain lesions and
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characteristics such as gender and age. Not much is known about the evolution of these
cerebral lesions, but it is apparent that these lesions are slow growing in nature. All of
the MRI examinations have taken place at the University of New Mexico Hospital. Dr.
Blaine Hart, a radiologist that specializes in the field of cerebral cavernous
malformations, was responsible for interpreting the MRI results of the patients in the
study. The MRI data including number of brain lesions was compared to the number of
skin lesions in our subjects. Inclusion criteria for those enrolled in AIM #2 was those
with a skin examination and an MRI examination that has occurred no more than 4
years prior to the skin examination. Exclusion criteria for this aim were those that had a
skin examination but did not have a brain MRI examination from the aforementioned
patient pool. In this aim we compared such factors as age, gender, type of lesion, and
skin lesion size with the number of brain lesions to attempt to recognize additional
correlations that could prove as being clinically important. A Spearman correlation was
completed to determine if there is a statistically significant relationship between the
number of skin lesions and the number of brain lesions. The research group felt that it
was important to identify any confounding relationships. Therefore, a Spearman
correlation was performed on the subgroup analysis as well.
Outcomes. We believe that the research group’s findings serve as a foundation for the
development of a valuable prognostic tool in the FCCM disease. If FCCM1-CHM
patients with increased numbers of cutaneous vascular malformations have increased
numbers brain lesions than cutaneous examination could provide a cost-effective
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approach to stratifying risk within this population. The following chapter discusses the
results of the research study.
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CHAPTER 3
RESULTS
Thirty-three participants with complete information on MRI brain lesions and
cutaneous lesions were included in the final analysis. Table 1 presents the descriptive
statistics for the variables of interest. The mean age of the sample is 46.3 years, and it
ranges from 10 to 73 years. The gender composition of the participants was 76%
female and 35% male. The average number of MRI brain lesions was 46.7, with a
maximum of 338. The participants had an average of 1.2 skin lesions, and ranged
between 0 and 4 lesions.
Table 1: Descriptive statistics

Age
Gender (female=1)
MRI brain lesions
Skin lesions

Obs.

Mean

Std. deviation

Min.

Max.

33

46.3

18.47

10

73

33

0.76

0.44

0

1

33

46.7

74.72

2

338

33

1.2

1.04

0

4

The main objective of the research study is to identify whether there is a
relationship between the number of cutaneous lesions and lesions in the central
nervous system as reported by MRI analysis. This data is presented graphically in
Figure 11. A Spearman correlation analysis reveals no significant relationship between
the number of cutaneous lesions and lesions in the central nervous system (r = 0.026, p
= 0.887). If we exclude brain lesions smaller than 0.5 cm, the degree of correlation
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seems to increase, but it is still not statistically significant under conventional standards
(r = 0.190, p = 0.374).

Figure 7.

As evident from the graphic representation above the number of cutaneous
lesions ranged from 0- 4 whilst the number of cerebral lesions ranged from 2- 338. This
large discrepancy indicated that there is no significant relationship. Therefore it can be
concluded that the number of cutaneous lesions cannot be used to hypothesize the
number of brain lesions. This does not completely exclude the findings of cutaneous
lesions as serving as a predictive factor for an individual to be evaluated for carrying the
CCM disease as these cutaneous lesions are related to a venous malformation. Given
that there is both sporadic and familial form of CCM these skin findings must be
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integrated with a past medical and family history. The presence of multiple cutaneous
vascular malformations may lend itself toward a germ line mutation or FCCM disease.
Cutaneous Lesions
Three types of cutaneous vascular malformations were identified in the study:
hyperkeratotic cutaneous capillary-venous malformations (HCCVM), punctate capillary
stains (PCS), and deep blue nodules (DBN).

Punctate Capillary Stain

Hyperkeratotic Cutaneous Cavernous Malformation (HCCVM)

Deep Blue Nodule

Figure 8. Example of cutaneous lesions identified in the CCM1-CHM population
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The classification used for the cutaneous vascular malformations identified in our
CCM1 subgroup is recommended by the International Society for the Study of Vascular
Anomalies. It is based on hemodynamic characteristics and predominant anomalous
channels (Enjolras et al, 1998). Research completed on other CCM1 positive cohorts
has implemented this classification as well. A total number of 53 lesions were identified
in 30 patients. The highest number of CVMs found in one patient was 4. Out of 53
lesions identified, 45 were acral lesions and 8 were truncal lesions. Spearman
correlation analyses reveal no significant relationship between skin lesions and MRI
brain lesions by location of the cutaneous lesion (acral: r = 0.027, p = 0.880; truncal: r =
0.153, p = 0.397). Although truncal lesions indicate a potentially stronger association
with brain lesions, the statistical significance does not reach conventional levels.
Cutaneous lesions were classified into three categories according to their size:
small if they measured less than 1.5 cm, medium if they were between 1.5 and 3 cm,
and large if they were larger than 3 cm. Out of the 53 lesions, 33 were identified as
small, six as medium, and 14 as large.
Eighteen of the cutaneous vascular malformations were deep blue nodules and
another 18 were punctate capillary stains. These comprised the most common types of
lesions. Additionally, out of the 53 lesions identified 13 were HCCVM. Four surgical
scars from vascular malformation removal were noted in the study. The research group
felt that it was important to include these scars in analysis as these represents
cutaneous lesions that should be included in the overall analysis. Reasons for having
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these cutaneous lesion removed were either pain due to the lesion or for cosmetic
purposes. Table 2 presents a summary of skin lesions by participant.
Table 2. Cutaneous Vascular Malformations
Participant ID

Total
lesions

16

3

18

2

23

2

26
39

2
1

45

4

52
64
102

2
1
2

103

3

115
141
157
158
203
206

1
1
2
2
1
1

239

2

246

1

259

2

269
304
316
348
392

1
1
1
2
3

360

3

Number of
lesions
1
2
2
1
2
2
1
1
2
1
2
1
2
2
1
1
1
2
2
1
1
1
1
1
1
1
1
1
1
2
3
2
1
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Lesion
subtype
DBN
PCS
HCCVM
HCCVM
PCS
HCCVM
DBN
PCS
DBN
Scar
DBN
HCCVM
PCS
HCCVM
DBN
HCCVM
PCS
DBN
DBN
PCS
PCS
DBN
HCCVM
PCS
DBN
HCCVM
PCS
Scar
PCS
Scar
DBN
PCS
DBN

Location
Acral
Acral
Acral
Truncal
Truncal
Acral
Acral
Truncal
Acral
Acral
Acral / Truncal
Truncal
Acral
Acral
Acral
Acral
Acral
Acral
Acral / Truncal
Acral
Acral
Acral
Acral
Acral
Acral
Acral
Acral
Acral
Acral
Acral / Truncal
Acral
Acral / Truncal
Acral

433

2

592
460
700
593

1
2
1
1

1
1
1
2
1
1

DBN
HCCVM
PCS
PCS
PCS
HCCVM

Acral
Acral
Acral
Acral / Truncal
Acral
Acral

As demonstrated above in Table 2 most lesions were determined to be located on
the extremities. Given the large number of brain lesions, it was anticipated that the skin
lesions would follow suit. The following graphic representation demonstrates that visibly
acral predominance of the cutaneous lesions.

Figure 9 Average Location of Cutaneous Vascular Malformations
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Demographics and Correlation Analysis
In addition to investigating the relationship between brain and skin lesions, the
relationship between cutaneous lesions and patient characteristics was examined. A ttest was used to compare the average number of cutaneous lesions in males and
females and a correlation study was performed to evaluate the relationship between
patient age and number of cutaneous lesions. The relationship between age and brain
lesions was also examined.
Spearman correlation was used to assess the relationship between patient age
and number of skin lesions present, and is shown in Figure 8. No significant association
was found between the two variables (r = -0.073, p = 0.686).
Figure 10.

Sirvente et al describes the cutaneous vascular malformations is his patient
group as being moderately evolving. He had found the nodular type vascular
malformations as being clearly able to increase over the years (Sirvente 2009). The
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small sample size of the CCM1 subgroup investigated in the study may be the reason
as to why no relationship was determined between age and skin lesions. It could also
be postulated that the CCM1-CHM cutaneous vascular malformations were most stable
and less apt to evolve over time.
Novel to any established literature on FCCM is the analysis of cutaneous lesion
differences between genders. The average number of cutaneous lesions was 1.25 for
males and 1.28 for females. The difference in the average number of skin lesions
across genders was compared using a two-tailed T-test. The conclusion was reached
that no significant difference exists in the average number of cutaneous lesions by
gender (p = 0.960). This can be extrapolated to indicate that the phenotypic penetrance
of CCM1- CHM between the genders is equal.
Although the research study focuses on the cutaneous lesions manifested by
FCCM disease, the research group attempted to identify a relationship between age
and brain lesions and gender and brain lesions. Unlike the cutaneous lesions, which
can be considered clinically benign, cerebral lesions can be potentially fatal. When
evaluating the relationship between age and MRI brain lesions through a Spearman
correlation analysis, it is found that there is a moderate positive correlation (r = 0.630, p
<0.001). This indicates that older individuals tend to present with more brain lesions.
Figure 9 shows that the relationship is increasing but not necessarily linear. This nonlinear relationship is further confirmed with a Pearson correlation analysis between age
and the logarithm of the number of brain lesions (𝜌=0.613, p <0.001). Figure 10
presents this relationship along with a linear prediction line.
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Figure 11.

Figure 12.

34

In terms of differences across genders, the average number of MRI brain lesions
for males was 19.38 and 55.40 for females. A one-tailed T-test finds that females have
a higher average number of brain lesions than males (p = 0.05). Given the results of the
cutaneous lesion comparison this again could be explained by the larger number of
females included in the sample group.
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CHAPTER 4
DISCUSSION
Comparing the data on skin lesions between our CCM1-CHM cohort and other
CCM cohorts it is evident that both differences and similarities exist. Eight five percent
of cutaneous vascular malformations were located on the extremities. A French study of
mostly CCM1 positive persons found 89% of lesions to be located on the extremities
(Sirvente 2009). This mirrors our findings. The majority of the lesion types were the
deep blue nodules and punctate capillary stains, which comprised 68% of the total
lesions. In a FCCM cutaneous study of a French cohort the most frequent cutaneous
malformation subtype were HCCVM and punctuate capillary stain cutaneous
malformation (Sirvente 2009). The majority of these persons were CCM1 positive. It is
interesting that the predominant lesion type is different between the two studies. The
difference may be related to the genetic founder affect. Our study population can be
considered more homogenous in this respect. Nonetheless, more investigation is
necessary to determine why the prevalence of a certain lesion subtype is different
between the two cohorts.
The cohort from whom the study participants were recruited most likely explains
the large number of females compared to males in the study. Females appeared to be
more connected to care regarding their CCM disease, therefore yielding a larger
amount of interest in the study. Review of previous studies on CCM1 positive
populations reveals that gender and age has not been investigated as a confounding
factor in analysis. The results gathered from this study are unique in that sense as the
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research group attempted to investigate these possible confounders. In our study,
gender was not correlated with a difference in cutaneous lesion number. Review of the
literature reveals that no other research group has investigated phenotypic difference
between genders. Labauge et al has determined that there exists a strong association
between a patient’s age and the number of cerebral lesions (Labauge 2007). Our
group’s findings reflect Labauge’s in that age (p < 0.001) was positively correlated with
increased cerebral lesion count. As a person ages the cerebral vascular malformations
become increasingly leaky. This would be the main reason for why there appears to be
increased cerebral lesions with increased age. Remarkably, the study revealed that
cutaneous lesion count and cerebral lesion count is not positively correlated (p = 0.686).
The reason that cutaneous lesions do not follow the same trend as cerebral vascular
malformations remains unknown. As the literature has shown, lesions in the skin
should follow suit. It is known that CCM proteins fulfill critical roles for endothelial cell
functions. This includes cell-to-cell junction formation and integrity, cell polarity, lumen
formation, and angiogenesis (Fischer 2013).
Enhanced permeability is a hallmark characteristic of CCM1 induced cerebral
lesions. This is the reason for both hemorrhage in the cerebrum and the violaceous to
blue coloration of the lesions in the skin. CCM proteins are also important in
angiogenesis. Loss of CCM1 or its interaction partner ICAP1 (ITG1BP1) impairs Delta–
Notch signaling. This results in excessive angiogenesis in human endothelial cells in
vitro and after transplantation into nude mice (Wustehube 2010). Given that the
mechanism of Krit-1 mutation functions the same way in angiogenesis in the cerebrum
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and cutaneous tissue, it would be expected that the number of cerebral lesions would
correlate with cutaneous lesions.
Much remains unknown regarding the different morphology of the cutaneous
malformations. Given that the pathogenesis of the leaky vasculature in the dermis is the
same in each type of lesion it would be expected that these lesions would have a similar
phenotypic manifestation. Indeed our findings have determined that there are in fact
three different subtypes of cutaneous lesions. It can be hypothesized that relative depth
to the surface of the skin determines the type of the lesion found. Further research
should be pursued investigating the histological difference between the lesions.
Considerations
One potential issue that the research group identified is access to the research
population. Because the population is spread throughout New Mexico it was difficult for
them to travel to the clinic for skin exams. Additionally the FCCM clinic occurs on
average once a month and serves only approximately 7 patients. By examining patients
from CCM clinic we had performed a convenience sample. A future consideration would
be to encourage family members of the patients that are also enrolled in the study to
present for examination. By doing so we can potentially increase the amount of patients
examined for the study purposes. It had been proposed during the research
development process that examinations occur in the household as well as the clinic in
order to increase the participation numbers. However, due to the fact that much of the
research relied on photographing patients, an appropriate setting had to be maintained.
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This is why we choose to examine the study population in a controlled clinic
environment.
We hoped to be able to photograph most of the cutaneous lesions in our
research population. Lesions located in sensitive locations on the subject’s body could
not be photographed per the research protocol. Subsequent evidence has
demonstrated that most of the CCM skin lesions are located acrally. Therefore the
research group was confident that we obtained a true and complete estimate of
cutaneous vascular lesions.
Difficulties encountered during the research process included obtaining data from
sufficient numbers of subjects to perform proper statistical analysis to produce
statistically significant results. This proved to be a challenge as the number of
cutaneous lesions in a subject ranged from 0 – 4. The number of brain lesions ranged
from 2 -338. Given the small sample size and the wide range of lesion numbers it is
difficult to establish a statistically significant correlation. Another reason for insignificant
statistical results was that patients must have had an MRI demonstrating CVMs and as
well as a skin examination. In some cases, persons that had cutaneous findings upon
skin examination did not have a documented MRI confirmation of brain lesions despite
being vetted as a CCM1-CHM carrier by genetic testing. These persons were excluded
from the study because the principal question investigated the relationship between
cutaneous and cerebral lesions. In the future we hope to confirm the number of cerebral
lesions in these patients via MRI, and ultimately include them in the study.
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The temporal association of the skin exam and MRI exam is an issue that has
been identified. It is logistically difficult to time the MRI exam with the skin exam.
However, because the skin lesions and cerebral lesions are slow growing throughout a
person’s lifetime, our research group expected that the timing of the exams would not
present a threat to validity.
Conclusions
Despite the absence of a significant relationship between skin and brain lesions it
was determined that the number of brain lesion increased with age. More research is
needed to determine the clinical significance of this. Characterization of the phenotypic
expression of the CCM1-CHM disease is key to being able to recognize and manage
this condition. An effort was made to determine all types of vascular lesions that are
associated with this disease. Research on other neuro-cutaneous disease reveals that
these types of cutaneous lesions are unique to CCM1.
Although cerebral cavernous malformations are not considered a true neurocutaneous disease, the utility of the cutaneous manifestation of disease can be
analogous to the usage of café-au-lait spots or hyperpigmented macules in the
diagnosis of neurofibromatosis type 1. Sturge Weber syndrome is yet another neurocutaneous disease that exhibits a cutaneous nevus flammeus (port-wine stain) in the
region of the first branch of the trigeminal nerve. This disease may also lead to seizures
and other neurologic problems (Nowak 2007). These associated skin findings have
been well known in the neurological community since the discovery of these syndromes.
These diseases are comparable to CCM in that they have both a neurologic and
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cutaneous component. The phenotypic expression of the CCM disease investigated by
this study is now vetted as a manifestation of the CCM1- CHM disease.
Familiarizing practitioners with variations of morphology of the skin lesions is key
to clinical identification of these lesions. The research group believes that this can be
accomplished through the achievement of the target research aim. In New Mexico,
where Familial Cerebral Cavernous Malformations is highly prevalent, identification of
cutaneous vascular malformations may serve as a valuable diagnostic tool for
practitioners. The catalogue of photographs of cutaneous vascular malformations can
be used to educate practitioners in the state of New Mexico. It can be published and
disseminated in the primary care, dermatology, and neurology community. Informing
practitioners in the state of New Mexico by using the photographic catalogue would be a
cost effective way to mitigating the deleterious affects of CCM on New Mexican families.
In conclusion, CCM1-CHM gene mutations may cause vascular skin lesions of
multiple different morphologies. FCCM disease should be suspected in patients with a
familial history of neurological abnormalities who have unique cutaneous venous
lesions. An early diagnosis of this condition is of great importance as it may result in
severe central nervous system disease that may be amenable to neurosurgical
rectification. The application of the catalogue of CCM1-CHM vascular malformations is
thus paramount in that it can be used to fast-track undiagnosed cases of FCCM. It can
serve as a visual screening tool to identify persons that may be living with the disease.
The research group believes that the comprehensive guide can be used to improve
public health throughout the state.
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Figure 13. Punctate capillary stain on the lower leg disguised as “pollen” on a lily flower tattoo.
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Appendix: Visual Database and Catalogue of CCM1-CHM Cutaneous Lesions
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